UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1117-15
Program Prior Authorization/Notification
Medication Xtandi® (enzalutamide)
P&T Approval Date 11/2012, 7/2013, 8/2013, 11/2014, 11/2015, 9/2016, 9/2017, 5/2018,
8/2018, 9/2019, 3/2020, 3/2021, 3/2022, 3/2023, 3/2024, 6/2024, 6/2025
Effective Date 9/1/2025
1. Background:
Xtandi® (enzalutamide) is an androgen receptor inhibitor indicated for the treatment of patients
with castration-resistant prostate cancer (CRPC), metastatic castration-sensitive prostate cancer
(mCSPC), and non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical
recurrence at high risk for metastasis (high-risk BCR).
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age of
19 years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or
under some circumstances. Some states also mandate usage of other Compendium references.
Where such mandates apply, they supersede language in the benefit document or in the
notification criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Xtandi will be approved based on the following criterion:
a. Patient is less than 19 years of age
Authorization will be issued for 12 months.
B. Prostate Cancer
1. Initial Authorization
a. Xtandi will be approved based on both of the following criteria:
(1) Diagnosis of prostate cancer
-AND-
(2) One of the following:
(a) Both of the following:
© 2025 UnitedHealthcare Services, Inc.
1
i. Disease is castration-resistant
ii. One of the following:
• Used in combination with a gonadotropin-releasing hormone (GnRH)
analog [e.g., Lupron (leuprolide), Zoladex (goserelin), Trelstar
(triptorelin), Vantas (histrelin), Firmagon (degarelix)]
• Patient has had bilateral orchiectomy
-OR-
(b) Both of the following:
i. Disease is metastatic castration-sensitive
ii. One of the following:
• Used in combination with a gonadotropin-releasing hormone (GnRH)
analog [e.g., Lupron (leuprolide), Zoladex (goserelin), Trelstar
(triptorelin), Vantas (histrelin), Firmagon (degarelix)]
• Patient has had bilateral orchiectomy
-OR-
(c) Disease is non-metastatic castration-sensitive with biochemical recurrence at
high risk for metastasis
Authorization will be issued for 12 months.
2. Reauthorization Criteria
a. Xtandi will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Xtandi therapy
Authorization will be issued for 12 months.
C. NCCN Recommended Regimens
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category
of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2025 UnitedHealthcare Services, Inc.
2
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits and/or Step Therapy may be in place.
4. References:
1. Xtandi [package insert]. Northbrook, IL: Astellas Pharma US, Inc. March 2025.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
https://www.nccn.org/professionals/drug_compendium/content/. Accessed April 28, 2025.
Program Prior Authorization/Notification - Xtandi (enzalutamide)
Change Control
11/2014 Annual review. Added ‘relapsed’ to prostate cancer criteria. Updated
background & references.
11/2015 Annual review. Revised prostate cancer criteria. Updated background &
references.
9/2016 Annual review. Updated references
9/2017 Annual review. Updated background and criteria to include NCCN
recommendation as initial androgen deprivation therapy for prostate cancer
in combination with a GnRH agonist. Updated references.
5/2018 Updated background and criteria to remove criteria for use as initial
androgen deprivation therapy as no longer recommended by NCCN.
8/2018 Updated background and criteria with to align with new indication in non-
metastatic setting. Updated criteria to include requirement to use in
combination with GnRH analog or bilateral orchiectomy as per label.
9/2019 Annual review with no changes to coverage criteria. Updated reference.
Added general NCCN recommended review criteria.
3/2020 Updated background and criteria to include new labeled indication for
metastatic castration-sensitive prostate cancer.
3/2021 Annual review. No changes to coverage criteria. Updated references.
3/2022 Annual review. No changes to coverage criteria. Updated references.
3/2023 Annual review with no change to coverage criteria. Updated references.
Added state mandate footnote.
3/2024 Annual review. Updated background and criteria with expanded indication
in non-metastatic castration-sensitive setting. Updated references.
6/2024 Updated criteria to reflect that for non-metastatic castration-sensitive
prostate cancer concomitant use with GnRH is not required.
6/2025 Annual review with no change to coverage criteria. Updated references.
© 2025 UnitedHealthcare Services, Inc.
3